Enveric Biosciences (STU:SLZ) Interest Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Enveric Biosciences's interest expense for the three months ended in Dec. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Enveric Biosciences's Operating Income for the three months ended in Dec. 2024 was € -3.03 Mil. Enveric Biosciences's Interest Expense for the three months ended in Dec. 2024 was € 0.00 Mil. Enveric Biosciences has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Enveric Biosciences Interest Expense Historical Data

The historical data trend for Enveric Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Interest Expense Chart

Enveric Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.37

-0.01

Enveric Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Enveric Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Enveric Biosciences (STU:SLZ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enveric Biosciences's Interest Expense for the three months ended in Dec. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-3.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €0.00 Mil.

Enveric Biosciences's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Enveric Biosciences had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Enveric Biosciences Inc has no debt.

Enveric Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ENVB:USA

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.